Mexican Scientist Eliminates HPV with Innovative Photodynamic Therapy

A researcher at the National Polytechnic Institute (IPN) in Mexico, Eva Ramón Gallegos, has announced the successful elimination of the Human Papillomavirus (HPV) in pilot studies using an innovative photodynamic therapy. This development offers a potential breakthrough in the fight against HPV, a virus responsible for a significant number of cervical uterine cancer cases worldwide.

Mexican Scientist Advances HPV Treatment with Novel Therapy

Eva Ramón Gallegos’s research has opened a promising new avenue for treating HPV. She developed a laser-based therapy that completely eliminates the virus through an innovative photodynamic process.

The scientist, affiliated with the Instituto Politécnico Nacional (IPN), achieved 100% eradication of HPV in patients without precancerous lesions during pilot studies. The therapy demonstrated a 64.3% success rate in women with HPV and cervical intraepithelial neoplasia grade I (CIN I), and lesion regression was observed in up to 83% of cases after 12 months of follow-up.

Did You Know? Eva Ramón Gallegos is an alumna of the National School of Biological Sciences (ENCB) of the IPN and has over 20 years of experience in nanobiotechnology applied to health.

Photodynamic therapy combines a photosensitive chemical agent with a laser light source. The process involves applying delta-aminolevulinic acid (5-ALA) to the cervix, where it accumulates in HPV-infected or precancerous cells. Exposure to laser light then activates the compound, generating reactive oxygen species that selectively destroy the damaged cells.

The therapy is non-invasive, outpatient-based, and does not cause serious side effects, making it a potentially valuable alternative for HPV treatment.

Ramón Gallegos’s research has been focused for years on therapies against viral diseases associated with cancer, particularly those affecting women in vulnerable situations.

Expert Insight: The development of a non-invasive treatment option for HPV, with demonstrated success in pilot studies, represents a significant step forward in preventative healthcare. The potential for high eradication rates and minimal side effects could dramatically improve treatment adherence and outcomes for women at risk.

Understanding Cervical Uterine Cancer

Cervical uterine cancer, also known as cervical cancer, develops in the cervix. It occurs when cells in the cervix grow abnormally and uncontrollably, forming a tumor.

Key causes and risk factors include:

Infection with the Human Papillomavirus (HPV)
Smoking
A weakened immune system
Family history
Early onset of sexual activity
Multiple sexual partners

Symptoms of cervical cancer can include:

Abnormal vaginal bleeding
Pelvic pain
Pain during intercourse
Abnormal vaginal discharge

Prevention and treatment options include HPV vaccination, regular Pap smears, treatment of precancerous lesions, and, for invasive cancer, surgery, radiation therapy, and chemotherapy.

Frequently Asked Questions

What is photodynamic therapy?

Photodynamic therapy combines a photosensitive chemical agent and a laser light source to selectively destroy damaged cells, in this case, those infected with HPV or exhibiting precancerous changes.

What were the results of the pilot studies?

The studies showed 100% HPV eradication in patients without precancerous lesions, a 64.3% success rate in women with CIN I, and lesion regression in up to 83% of cases after 12 months.

What is cervical uterine cancer?

Cervical uterine cancer is a cancer that develops in the cervix, often caused by abnormal cell growth triggered by HPV infection.

As research progresses, this therapy could become more widely available, potentially offering a new and effective treatment option for HPV and reducing the incidence of cervical cancer.